US74366E1029 - Common Stock
PROTAGONIST THERAPEUTICS INC
NASDAQ:PTGX (5/17/2024, 7:21:40 PM)
After market: 30.74 0 (0%)30.74
-1.2 (-3.76%)
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 111 full-time employees. The company went IPO on 2016-08-11. The firm uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. Its clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned, investigational, orally delivered, gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
PROTAGONIST THERAPEUTICS INC
7707 Gateway Blvd Ste 140
Newark California CALIFORNIA 94560
P: 15104740170
CEO: Dinesh V. Patel
Employees: 111
Website: https://www.protagonist-inc.com/
PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Protagonist Therapeutics (NASDAQ:PTGX) just reported results for the first quar...
Protagonist Therapeutics shares surge as it enters a global collaboration with Takeda for the development of its investigational drug, rusfertide.
Here you can normally see the latest stock twits on PTGX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: